Moberg Pharma AB

As of June 30, 2026, Moberg Pharma AB carries a market capitalization of 40.06M, placing it among publicly traded companies globally. Its enterprise value stands at 21.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Moberg Pharma AB's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Moberg Pharma AB has 47.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 26.33, and the price-to-book ratio stands at 0.67.

These figures are as of June 30, 2026. The EV/Sales ratio of 13.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 21.03M versus a market cap of 40.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Moberg Pharma AB maintains a current ratio of 12.25, meaning it holds 12.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.26, indicating conservative leverage, while an interest coverage ratio of -133.55 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Moberg Pharma AB posted a negative return on equity (ROE) of -3.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.11, reflecting losses generated across the asset base. The company generates approximately 252,219.31 in revenue per employee across its workforce of 6.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.12 indicates how many times Moberg Pharma AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Moberg Pharma AB recorded 399,409.93 in income tax expense. The company reported a pretax loss of -1.55M and -1.95M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Moberg Pharma AB's stock has gained approximately 35.11% over the past 52 weeks. The 50-day moving average sits at 0.99, while the 200-day moving average is 0.94.

Over the twelve months ended June 30, 2026, Moberg Pharma AB generated 1.51M in revenue and converted that into -1.95M in net income, yielding earnings per share of -0.04. EBITDA reached -1.66M, while operating income came in at -1.81M.

As of June 30, 2026, Moberg Pharma AB holds 19.18M in cash and equivalents against 155,195.68 in total debt, resulting in a net debt position of -19.18M. Total book value stands at 59.85M, with working capital of 18.77M providing operational flexibility.

Moberg Pharma AB produced -1.21M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -987,510.36 in capital expenditures, free cash flow totaled -2.20M - equivalent to -0.05 per share.

Over the twelve months ended June 30, 2026, Moberg Pharma AB posted a gross margin of 62.31, reflecting its pricing power and cost economics. The operating margin of -119.54 and net profit margin of -128.96 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.37: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Moberg Pharma AB shareholders.

Moberg Pharma AB's most recent stock split took place on August 11, 2023 with a 2:3 split ratio.

As of June 30, 2026, Moberg Pharma AB has an Altman Z-Score of 12.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.